2016
DOI: 10.1155/2016/1567254
|View full text |Cite
|
Sign up to set email alerts
|

Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice

Abstract: Severe hepatosplenic injury of mansonian schistosomiasis is caused by Th2 mediated granulomatous response against parasite eggs entrapped within the periportal tissue. Subsequent fibrotic scarring and deformation/sclerosing of intrahepatic portal veins lead to portal hypertension, ascites, and oesophageal varices. The murine model of Schistosoma mansoni (S. mansoni) infection is suitable to establish the severe hepatosplenic injury of disease within a reasonable time scale for the development of novel antifibr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 11 publications
(15 citation statements)
references
References 22 publications
0
15
0
Order By: Relevance
“…The panel of assays to study hepatocyte function and viability employed in this study has been previously patented for the early detection of patients endangered for the development of liver dysfunction during sepsis [ 15 , 16 ]. Further standardization was done by the employment of the panel for screening purposes during extracorporeal treatments and for an experimental model of liver dysfunction in Schistosoma infections [ 30 , 31 ]. It utilizes the human hepatocellular carcinoma cell line HepG2/C3A, a well-characterized subclone of the hepatoma-derived HepG2 cell line often used for toxicological screening [ 32 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…The panel of assays to study hepatocyte function and viability employed in this study has been previously patented for the early detection of patients endangered for the development of liver dysfunction during sepsis [ 15 , 16 ]. Further standardization was done by the employment of the panel for screening purposes during extracorporeal treatments and for an experimental model of liver dysfunction in Schistosoma infections [ 30 , 31 ]. It utilizes the human hepatocellular carcinoma cell line HepG2/C3A, a well-characterized subclone of the hepatoma-derived HepG2 cell line often used for toxicological screening [ 32 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…We paid special attention to the different, widely spread infection intensities in order to investigate whether these differences can be quantified by MRI or PET/CT. We have used the system of 25, 50 and 100 cercariae in the past to analyze mild, moderate and severe clinical picture 34 . However, histological analyses of the granuloma sizes and collagen fibers within the livers using HE and SR staining revealed comparable results.…”
Section: Discussionmentioning
confidence: 99%
“…S. mansoni cercariae were obtained by mass shedding of 5-10 infected B. glabrata after day light exposure. With our experimental design we aim to investigate three widely differing infection intensities and degrees of liver damage 34 . Each mouse was exposed to parasites by sitting in a water bath enriched with 25 (n = 4, light infection), 50 (n = 5, moderate infection) and 100 (n = 5, high infection) S. mansoni cercariae for 90 min.…”
Section: Schistosoma Mansoni Infection Model and Study Design Schistmentioning
confidence: 99%
“…The antimycotics were tested in an established microtiter plate assay for screening of hepatotoxicity [ 19 – 22 ]. HepG2/C3A cells were seeded in 24-well plates at 500.000 cells/well and were incubated for 72 hours with the different drugs in 1 ml medium or heparinized plasma from healthy volunteers (pooled plasma).…”
Section: Methodsmentioning
confidence: 99%
“…Therefore, therapeutic drug monitoring (TDM), in combination with clinical assessment of the therapeutic effect, may help to optimize treatment results [ 18 ]. The aim of the presented study was to determine the hepatotoxicity of antimycotics used for systemic infections with human hepatocytes (HepG2/C3A) in an established in vitro cytotoxicity screening model [ 19 – 22 ].…”
Section: Introductionmentioning
confidence: 99%